2020年ASCO会议食管及食管胃交界癌放疗与综合治疗进展

Progress in radiotherapy and comprehensive treatment of esophageal and esophagogastric junction cancer presented at the 2020 ASCO annual meeting

食管癌是我国最常见的恶性肿瘤之一,早期发现率较低,大多数患者确诊时已属于中晚期,预后较差,5年生存率很低。放疗在食管癌治疗中发挥着重要作用,尽管目前放疗技术有了较大的改进,但也无法大幅度地提高生存率,总体疗效不够满意。放疗照射剂量方面的研究已处于瓶颈期,目前研究主要集中在化疗药物、靶向药物和免疫药物与放疗联合的综合治疗领域,本文就2020年ASCO会议上多项食管及食管胃交界癌放疗与综合治疗的研究成果予以汇总,并结合近年来该领域的相关研究进行综述。

Esophageal cancer is one of the most common malignant tumors in China.Its early diagnosis rate is low,with most patients already in an advanced disease stage at the time of diagnosis;patient prognosis is poor;and 5-year survival rate is low.Radiotherapy plays an important role in treating esophageal cancer,and although radiotherapy techniques have greatly improved,they still do not significantly improve the survival rate and overall efficacy.Research on radiation dose is in the midst of bottleneck period,whereas chemotherapy,targeted therapy,and immunotherapy combined with radiotherapy are becoming the hotspots.This review summarizes research advamcement regarding radiotherapy and comprehensive treatment of esophageal and esophagogastric junction cancer at the 2020 ASCO annual meeting and recent years.